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了 6679 亿元，医药工业占 GDP 的比重上升至 3%。2011 年，医药工业总产值
有了质的提升，达到 14522 亿元，同时，其在国民经济中的地位不断提升，行业































Pharmaceutical industry is a high-tech industry integrated with traditional 
civilization and modern technology, and is directly related with the national economy 
and people’s livelihood. With the improvement of people’s living standard, 
acceleration of population aging process, establishment of public health-care system 
and deepening of medical care system reform, pharmaceutical industry is playing an 
ever integral part in the national economy, casting substantial influence on the level of 
medical care the general public is entitled to. 
The past few years have witnessed rapid development of pharmaceutical industry 
in China. In 2007, gross output of pharmaceutical industry stood at RMB667.9 billion 
and it accounted for 3% of GDP, while in 2011 its gross output reached RMB1452.2 
billion. With its increasing importance in the national economy, the percentage of 
pharmaceutical industry out of GDP has been on a steady increase. As of the first half 
of 2012, it took up 3.42% in the national economy.  
The exponential development of pharmaceutical industry is attributed to the low 
elasticity of demand as well as the promulgation of medical care reform policies. The 
rapid increase of the industry thus generates a huge demand for financing and as a 
healthily developing industry, it has become a favored credit customer for banking 
institutions.  
The paper is focused on how to provide the optimum financing solution to 
pharmaceutical industry and how banking institutions control risks while meeting the 
financing requirement to achieve win-win situation between banks and 
pharmaceutical companies.  
The writer studies the current status of pharmaceutical industry in Fujian 
Province and successful cases of banking institutions involving in pharmaceutical 
industry. With years of experience in the credit business for commercial banks, the 
writer proposes feasible recommendations and proposals in the following three 
aspects with regard to credit business for pharmaceutical industry in Fujian Province: 
1) In consideration of the special characteristics of supply chain in pharmaceutical 
industry, supply chain financing business would be given priority, with clearly 















like Bio Park to provide joint credit service and establish cooperation between banks 
and pharmaceutical companies; 3) To well manage the credit risk in the 
pharmaceutical industry to guarantee the security of credit funds and achieve win-win 
for banks and pharmaceutical companies.  
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第一章  绪论 
 1
第一章  绪论 
一、研究背景和意义 
近年来，我国医药行业发生了飞速的发展。医药工业总产值从 1978 年的
79 亿元增加到 2007 年的 6679 亿元，30 年间翻了 84.5 倍；医药工业占 GDP 
的比重从 1978 年的 2%上升至 2007 年的 3%1。医药行业作为制造业中一个较小
的行业，其在国民经济中整体所占比重不大，但 2005-2012 年，随着国民经济
的快速发展，我国医药制造行业生产总产值一直呈上升趋势，从 2005 年的 
3365.85 亿元，增加至 2011 年的 14522 亿元，增加为原来的 4.3 倍，行业保
持较快增长速度2。同时，随着经济的快速发展，以及人口社会因素的内生性需
求，我国医药行业规模在不断扩大的同时，其在国民经济中的地位不断提升，行
业总产值占 GDP 比重一直保持平稳增长态势。从 2005 年的 1.82%增加至 2012
年上半年的 3.42%，行业所占比重平稳增长。 
随着中国医药行业的快速发展，医药产业投资保持快速增长，尤其是 2009
年以来，增速达到 30%以上，2011 年，投资增速为 45.5%，增速达到历史 高水
平。2012 年上半年，中国医药产业投资的高增长态势不改。受国家实施新版《药
品经营质量管理规范》等因素影响，医药产业投资继续高速增长，累计完成投资
1456.70 亿元，同比增长 40.6%，高出制造业 16.1 个百分点。中国医药行业投资
保持高速增长，可见行业存在较大的融资需求。 
据银联信相关数据统计，2012 年 1-6 月，全国医药行业累计利息支出 75.01
亿元，同比增长 33.62%，占销售收入比重为 0.97%。利息支出同比增速保持较高





                                                        
1 银联信相关统计数据 
2 中国医药行业信息网 
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